The Sleep-Discontinuation Dilemma: New Data on Hypnotics in Chronic Insomnia
A large-scale Japanese claims database study published in Psychiatry and Clinical Neurosciences provides critical real-world evidence on the discontinuation rates of different classes of hypnotics used for chronic insomnia. The research analyzed data from over 4,400 patients who received at least three consecutive prescriptions. It found that dual orexin receptor antagonists (DORAs) had a significantly higher rate of discontinuation compared to traditional benzodiazepines, with a hazard ratio of 1.40. This suggests patients on DORAs were more likely to stop their medication, potentially indicating a shorter-term treatment pattern or different tolerability profile. The study also identified that older age and a higher number of comorbid conditions were associated with a lower likelihood of discontinuing any hypnotic, highlighting the complexity of managing chronic insomnia, especially in patients with multiple diagnoses.
Study Significance: For rheumatologists managing patients with chronic pain conditions like fibromyalgia, where sleep disturbances are a core symptom, this data on real-world hypnotic use is highly relevant. Understanding the discontinuation profiles of newer agents like DORAs can inform more nuanced treatment strategies, potentially favoring agents that patients are more likely to adhere to over time. This evidence supports a shift towards personalized pharmacotherapy in managing the insomnia that frequently accompanies chronic inflammatory and pain disorders, moving beyond efficacy alone to consider real-world persistence and patient-specific factors.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
